Prostate cancer gene hunt could spot relapse early
NCT ID NCT03421015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at genetic changes in prostate cancer samples from 84 men who had surgery. The goal was to find DNA markers that could predict if the cancer would come back or spread. By identifying these markers, doctors may one day better tailor follow-up care and treatment for high-risk patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
84 people
The number who actually took part.
- Started
-
May 2017
- Finished
-
Jul 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients managed by radical prostatectomy for prostate cancer
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016. * Follow up \> 6 years * Negative pre surgical extension assessment * Prognostic Grade Groups (OGG) III-IV-V * Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL * Metastasis positive imaging Exclusion Criteria: * Neoadjuvant therapy * Follow up \< 6 years * Prognostic Grade Groups (PGG) I-II * Biochemical recurrence with metastasis negative imaging
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostatic neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Claude Huriez, CHRU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI spot which prostate cancers are safe to watch?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Radiation boost may extend Drug-Free time in prostate cancer recurrence
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?